GRP and neoplasm: Similar results were observed among stage I and II patients using the combination of Discriminant- 3 and three tumor markers (CEA, SCC, and NSE), while no significant improvement of sensitivity was observed using Discriminant- 3 and CYFRA or ProGRP (Figure 3).